SHARE: +/-: -0.08 SEK / Bid: 7.64 SEK / Ask: 7.78 SEK / Price: 7.82 SEK / High: 7.94 SEK / Low: 7.62 SEK / Quantity: 37 056 / Turnover: 285 084 SEK / 2021-01-27 16:26 (CET)
 

Press releases

Extended SpagoPix patent protection in Europe

Spago Nanomedical AB (publ) has received notice from the European Patent Office (EPO) that it intends to grant the company´s patent application including a critical component of the SpagoPix candidate drug SN132D. The granted patent will extend protection of SpagoPix in Europe until at least 2038. EPO has issued an…
Read more

Invitation to webcast

In connection to the interim results of the clinical study SPAGOPIX-01, the company invites to a live webcast today at 13:00. CEO Mats Hansen will present and comment the results, and provide opportunity for questions. The webcast can be reached by: https://www.finwire.tv/webcast/spago-nanomedical/q3/. The webcast will be available afterwards at the…
Read more

Distinct images in clinical study with SpagoPix

Interim results from the phase I study SPAGOPIX-01 show that SN132D provides MRI contrast enhancement in breast tumors. In line with previous preclinical data the clinical results confirm accumulation of the unique nanomaterial in solid tumors. In addition, unexpectedly good contrast in the pancreas has been observed in all images…
Read more

Spago Nanomedical appoints candidate drug in the Tumorad® project

Spago Nanomedical AB (publ) has demonstrated, with statistical significance, that Tumorad® reduces tumor growth and extends survival in a mice model for breast cancer. Based on this result and previously communicated progress in the project, the company has decided to formally appoint candidate drug (“CD”) and prepare the preclinical safety…
Read more

Tumorad® patent approval in Japan

Spago Nanomedical has received notice of allowance for the company´s patent application including Tumorad® product protection in Japan. ”The patent covers the nanomaterial that is central for the Tumorad®-project. As Japan represent a potentially large market for radionuclide therapies, this approval is important. It also underscores the quality of our…
Read more

SpagoPix phase I study to next dose level and expansion to additional site

Data from the first dose group in the phase I trial show that SN132D is well tolerated, and provide valuable information for optimization of MRI in the next step. Now that the study continues into the next dose level the company intend to up the pace in patient recruitment by…
Read more

Lead compound appointed in the Tumorad® -project

Spago Nanomedical has appointed lead compound in the Tumorad®-project and is now proceeding development into pre-clinical proof-of-concept validation in tumor models.   ”Nomination of lead compound is an important step marking that we now hold a material that fulfills our strict requirements on pharmacokinetic and chemical properties for selective accumulation…
Read more

First patient dosed in the SPAGOPIX-01 study

The first patient in the clinical study SPAGOPIX-01 has been successfully dosed with the contrast agent SN132D and completed MRI.   The clinical study SPAGOPIX-01 is conducted at the Uppsala University Hospital in Sweden and will include up to 20 patients with with confirmed breast cancer. The primary objective is…
Read more

Spago Nanomedical has initiated the clinical trial SPAGOPIX-01

Spago Nanomedical AB (publ) has conducted site initiation visit at the Uppsala University Hospital in Uppsala and formally opened the first clinical trial with the tumor selective contrast agent SpagoPix (SN123D). The trial will include up to 20 patients with confirmed breast cancer.   The primary objective with the trial…
Read more

Spago Nanomedical to present preclinical data for SpagoPix at ECR

Spago Nanomedical AB (publ) will present preclinical data for SpagoPix at the conference European Congress of Radiology (ECR) this week The presentation, in the form of a poster with the title ”Efficacy and safety profile of SN132D, a novel nanoparticle MRI contrast agent”, includes preclinical data that collectively show that…
Read more